You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for Patent: 8,765,167


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,765,167
Title:Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Abstract: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.
Inventor(s): Myers; Garry L. (Kingsport, TN), Sanghvi; Pradeep (Schererville, IN), Verrall; Andrew Philip (Crown Point, IN), Francis; Vimala (Fremont, CA), Moss; Laura (Schererville, IN)
Assignee: MonoSol Rx, LLC (Portage, IN)
Application Number:11/517,982
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,765,167
Patent Claim Types:
see list of patent claims
Compound; Process; Delivery;

Drugs Protected by US Patent 8,765,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aquestive EXSERVAN riluzole FILM;ORAL 212640-001 Nov 22, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,765,167

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077803 ⤷  Sign Up
Austria 536868 ⤷  Sign Up
Austria 536869 ⤷  Sign Up
Austria 553746 ⤷  Sign Up
Australia 2002332118 ⤷  Sign Up
Australia 2002348432 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.